CD137L和结直肠癌的预后:从临床和TCGA数据分析的见解
1Department of Gastrointestinal Surgery, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, 100038, People's Republic of China.
Cancer biomarkers : section A of Disease markers
|November 5, 2025
概括
结肠直肠癌中CD137L表达率较高与患者生存率的改善相关,并与瘤分期有关. 这表明CD137L (集群分化137联结体) 可能是结直肠癌预后生物标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 集群分化137联体 (CD137L) 涉及免疫调节和瘤进展.
- 它在结直肠癌 (CRC) 中的作用和表达尚未得到充分理解.
- 调查CD137L对于理解CRC病变发生和识别预后标记物至关重要.
研究的目的:
- 评估结直肠癌组织中的CD137L表达水平.
- 确定CD137L表达和临床病理学特征之间的关联.
- 调查CD137L表达和结直肠癌患者存活率之间的关系.
主要方法:
- 量化实时PCR (qRT-PCR) 用于测量36个结直肠癌组织样本中的CD137L表达.
- 对表达式分析使用了比较 ΔΔCt 方法,对 GAPDH 进行正常化.
- 使用TCGA数据库进行生存分析和研究差异表达基因.
主要成果:
- CD137L的表达与患者的存活率有显著的相关性 (P<0.05),存活患者的水平更高.
- 在CD137L表达和瘤分期之间发现了显著的关联 (P = 0.03).
- TCGA数据分析显示,增加CD137L表达与改善结直肠癌患者的整体存活率有关.
结论:
- CD137L表达是结直肠癌的显著预后指标.
- CD137L可能参与结直肠癌的进展和免疫调节.
- CD137L显示出作为预测结直肠癌患者结果的生物标志物的潜力.
更多相关视频
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.9K
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
482
相关概念视频
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
01:21Cancer Survival Analysis
639
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
639
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K